Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

(2018) Tiffany A. Traina et al.   JOURNAL OF CLINICAL ONCOLOGY

Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer

(2018) Yundong He et al.   NUCLEIC ACIDS RESEARCH

Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer

(2017) Alfonso Urbanucci et al.   Cell Reports

AR Signaling in Breast Cancer

(2017) Bilal Rahim et al.   Cancers

Nucleophosmin: from structure and function to disease development

(2016) Joseph K. Box et al.   BMC MOLECULAR BIOLOGY

Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer

(2016) Andrew J. Robles et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer

(2016) Yuka Asano et al.   BRITISH JOURNAL OF CANCER

In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment

(2016) J. Perez-Pena et al.   MOLECULAR CANCER THERAPEUTICS

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

(2016) Shaokun Shu et al.   NATURE

Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer

(2016) Damien Destouches et al.   Oncotarget

Anti-androgen therapy in triple-negative breast cancer

(2016) Valerie N. Barton et al.   Therapeutic Advances in Medical Oncology

Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level

(2015) Theodoros Karantanos et al.   EUROPEAN UROLOGY

Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo

(2015) V. N. Barton et al.   MOLECULAR CANCER THERAPEUTICS

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

(2013) Jakob Lovén et al.   CELL

Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer

(2013) A. Gucalp et al.   CLINICAL CANCER RESEARCH

Androgens Upregulate Cdc25C Protein by Inhibiting Its Proteasomal and Lysosomal Degradation Pathways

(2013) Yu-Wei Chou et al.   PLoS One

BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia

(2013) D Da Costa et al.   Blood Cancer Journal

Targeting triple-negative breast cancer: optimising therapeutic outcomes

(2012) K. Gelmon et al.   ANNALS OF ONCOLOGY

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins

(2012) W. W. Lockwood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy

(2011) Sibylle Loibl et al.   BREAST CANCER RESEARCH AND TREATMENT

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

The AR dependent cell cycle: Mechanisms and cancer relevance

(2011) Matthew J. Schiewer et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Triple-Negative Breast Cancer: An Unmet Medical Need

(2011) C. A. Hudis et al.   ONCOLOGIST

Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer

(2010) Ali Naderi et al.   CANCER LETTERS

ANCCA/ATAD2 Overexpression Identifies Breast Cancer Patients with Poor Prognosis, Acting to Drive Proliferation and Survival of Triple-Negative Cells through Control of B-Myb and EZH2

(2010) E. V. Kalashnikova et al.   CANCER RESEARCH

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers

(2010) C Caron et al.   ONCOGENE

Androgen-Induced Coactivator ANCCA Mediates Specific Androgen Receptor Signaling in Prostate Cancer

(2009) J. X. Zou et al.   CANCER RESEARCH

ATAD2 Is a Novel Cofactor for MYC, Overexpressed and Amplified in Aggressive Tumors

(2009) M. Ciro et al.   CANCER RESEARCH